



Massachusetts General Hospital
Corporate & Foundation Relations
Office of Development

PRIVATE FUNDING OPPORTUNITIES: OCT 21, 2016

Please contact Corporate & Foundation Relations in the Office of Development at devcfr@mgh.harvard.edu if you wish to submit a proposal in response to any of these opportunities. Note that proposals are still routed through the standard InfoEd/Research Management process.

1. Research Grants, Meningitis Research Foundation New

The foundation is inviting proposals dealing with all forms of meningitis and associated infections, improving prevention, treatment and outlook for patients, and improving the speed and accuracy of diagnosis.

The foundation's Scientific Advisory Panel and Trustees are currently highlighting the following topics:

- Research pertinent to prevention of bacterial meningitis and to maximising vaccine impact, including studies to:
 - a. evaluate vaccines or enable their evaluation
 - b. understand their mode of action
- Research leading to prevention of neonatal meningitis and sepsis, including research which facilitates GBS vaccine development and implementation
- Research in Africa that seeks to improve outcomes from meningitis by:
 - a. overcoming barriers to health seeking behaviour
 - b. improving prevention, treatment or health systems
 - c. improving recognition and accelerating the development and evaluation of rapid diagnostic tests (RDTs) for meningitis

The foundation is particularly interested in projects that lead to practical interventions and partnerships in Africa.

In setting priority topics, the foundation's aim is to elicit strong, well-constructed research proposals on subjects they believe will have the most impact in terms of clinical/public health benefit or unlocking key research questions that will enable further translational research. The foundation will consider funding basic science, but this must increase understanding of the disease area and have a clearly defined potential for early translation into alleviation of the diseases. Research funded must be of the highest scientific merit, in terms of the importance of the investigation, excellence of the study, ability of the research team, and probability of success.



Do you want to learn more about identifying external funding opportunities? See [ECOR's website](#) for information on the funding opps database, **COS Pivot** or contact Amy Robb <arobb@mgh.harvard.edu> to schedule an individual consultation or group training session.

Award Amount: Up to £750,000 GBP paid over 5 years

Indirect Costs: Unpublished

Preliminary Proposal Deadline: Nov 25, 2016

Website: <http://www.meningitis.org/grants>

2. Research Grants, PSC Partners Seeking a Cure

PSC Partners offers grants to conduct research that addresses an important and novel, basic or clinical research question related to primary sclerosing cholangitis and closely associated diseases (such as inflammatory bowel diseases (IBD), ulcerative colitis (UC) or Crohn's disease) as they relate to PSC. The applicant must be at an academic institution with an interest in pursuing PSC as an indication for treatment. The purpose is to encourage investigators to conduct research in promising new areas with the goal that data generated will lead to federal (NIH) funding.

PSC Partners Seeking a Cure is particularly interested in funding research projects that have the potential to discover a cure for this disease, and/or identify novel therapies that may significantly delay time to liver transplantation, prevent disease recurrence following liver transplantation, and/or improve the quality of life of those with PSC. PSC Partners understands that much fundamental research is necessary to discover the environmental factors that may trigger this disease in genetically susceptible individuals, and therefore we would like to encourage research proposals aimed at identifying the gene-environment interactions contributing to disease initiation and progression. PSC Partners recognizes that studies with animal models may be appropriate to address these fundamental questions. We are interested in funding research that explores PSC-related diseases (IBD, UC, and Crohn's disease) in ways that they impact, enable, or perhaps cause PSC. PSC Partners encourages research that will be complementary to the goals and objectives of the International PSC Study Group, including investigation of the functional roles of genes associated with susceptibility to and severity of PSC. Other priority areas for research include the mechanisms of PSC pathogenesis and colorectal and cholangiocarcinoma carcinogenesis as well as strategies for prevention. Applications focused on assessing and improving the quality of life of PSC patients are also encouraged. Proposals that have little relevance to PSC will not be considered for funding. We strongly encourage interdisciplinary collaborations and the sharing of resources as a means of accelerating progress in PSC research. If the proposal includes a specific plan for sharing of results and resources (such as DNA), this will result in a more favorable review. Applications addressing PSC in children are strongly encouraged.

Award Amount: \$60,000 paid over 2 years

Indirect Costs: None

Application Deadline: Apr 17, 2017

Website: <http://pscpartners.org/research-grants/grant-application/>

3. Pfizer Independent Grants for Learning & Change (IGLC): Request for Proposals (RFP) - Accelerating Improvements in Medication Optimization, Pfizer, Inc. New

Pfizer Independent Grants for Learning & Change (IGLC) and the Institute for Healthcare Improvement (IHI) are collaborating to offer a new grant opportunity focused on medication optimization, a concept developed by IHI that is focused on four key areas for medication management: 1) optimal medication selection (including shared decisions that incorporate patient preferences and circumstances); 2) coordinated prescribing among providers; 3) clear timeframes for medication duration and follow-up; and 4) improved adherence.

Medication optimization recognizes that, in addition to the package of possible therapeutic recommendations, it is critical to take into consideration aspects of an individual's life that impact medication adherence and management. The goal of this Request for Proposals (RFP) is to support the development of processes and practices that optimize medication prescribing for and treatment of patients with rheumatoid arthritis (RA).

The mission of IGLC is to partner with the global health care community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. "Independent" means that the projects funded by Pfizer are the full responsibility of the grant recipient organization. Pfizer has no influence over any aspect of the funded projects and asks only for reports about the results and the impact of the projects in order to share them publicly.

The IHI is a leading innovator in health and health care improvement worldwide. For more than 25 years, IHI has partnered with visionaries, leaders, and frontline practitioners around the globe to spark bold, inventive ways to improve the health of individuals and populations. IHI is recognized as an innovator, convener, trustworthy partner, and driver of credible results based on scientific quality improvement methods. To advance its mission, IHI's work is focused in five key areas: Improvement Capability; Person- and Family-Centered Care; Patient Safety; Quality, Cost, and Value; and Triple Aim for Populations. A strategic goal of IHI is to reduce disparities in health and health care, promoting equity in the US and globally.

IGLC and IHI encourage organizations with an interest in improving management of RA, including medication optimization, to submit a proposal in response to this RFP.

Geographic Scope: United States Only

Clinical Area: Medication optimization for adult rheumatoid arthritis patient populations

Target Audience: Healthcare providers caring for adult patients with rheumatoid arthritis and the patients themselves

Specific Area of Interest for this RFP: This RFP is focused on designing and evaluating innovative programs that optimize medication regimens for adult rheumatoid arthritis patients

in any clinical setting in the United States. The intent is to support the development and adoption of approaches that lead to medication optimization resulting in treatment that has high therapeutic benefit, lower risk of harm, lower anxiety and emotional stress for patients, conforms to principles of patient- and family-centered care and shared decision making, and potentially lower overall costs of care.

Medication optimization can involve at least four key components:

1. Optimal medication selection
2. Coordinated prescribing among providers
3. Clear timeframes for medication duration and follow-up
4. Improved adherence.

It is expected that research projects will focus in on one or more of the above listed components and will follow generally accepted scientific principles. Applicants may utilize other helpful frameworks so long as their theory and research base is outlined in their proposal.

Projects that include the following factors will be given high priority:

- Utilization of scientific improvement principles and methods: Organizations may use a variety of improvement principles and or methods (e.g., Lean, Lean SixSigma, Model for Improvement.)
- Reducing disparities in the care of patients: IGLC and IHI place a high priority on reducing disparities in the care of patients with chronic conditions such as RA. To be considered, all proposals must indicate how the applicant will identify and address equity in the population it serves.
- Maximum likelihood to directly impact patient care: Projects with maximum likelihood to directly impact patient care will be given high priority. Projects should include an educational element to the research intervention.

It is not the sponsors' intent to support clinical research projects that seek to evaluate new therapeutic or diagnostic modalities.

Award Amount: \$200,000 paid over 2 years

Indirect Costs: 28%

Proposal Deadline: Nov4, 2016

Website: http://www.pfizer.com/responsibility/grants_contributions/request_proposals

4. Research Grants, Terri Brodeur Breast Cancer Foundation (TBBCF)

The foundation is dedicated to providing critical funding to researchers investigating breast cancer cures and patient treatment options. The foundation is founded on the pledge of delivering 100 percent of gross fundraising dollars to breast cancer science. The foundation's Grant Program seeks to augment clinical and pre-clinical fellowships in high impact, breast cancer therapeutic research areas.

This award is intended to support individuals to enable them to develop independent careers in breast cancer research. The foundation seeks to fund broadly across all relevant disciplines and as such focus areas can include basic, preclinical and clinical research.

Award Amount: Up to \$50,000 paid over 2 years

Indirect Costs: Unpublished

Pre-Application Deadline: Nov 12, 2016

Website: <http://terribrodeurbreastcancerfoundation.org/granting-process/>